Exopharm Limited announced that the results from its PLEXOVAL II phase I safety study with the company's off-the-shelf (allogeneic) platelet-derived EV product, Plexaris, found there were no untoward or unexpected safety events reported during the study with all 11 enrolled participants remaining healthy throughout and after their 30-day follow- up period. The phase 1 study demonstrated the safety of off-the-shelf Plexaris in a cutaneous wound healing condition, concluding that there are no safety risks associated with the use of the product or the injection of the product. The first-in-human study of Plexaris was a prospective randomised double-blind, placebo-controlled study aimed at demonstrating the safety of the product administered to healthy adult volunteers as a single dose subcutaneously at the site of a skin punch biopsy-induced wound.